Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding
Metaanalyse zu Palmitoylethanolamid bei der Schmerztherapie: Literaturlücken schließen und Verständnis verbessern
Nutrition Reviews · 01.07.2025 · 83 (7) · e1604-e1618
DOI: 10.1093/nutrit/nuae203 ↗Auf einen Blick
Eine Metaanalyse von 18 RCTs mit 1.196 Patient:innen untersuchte Palmitoylethanolamid (PEA) bei Schmerz. PEA reduzierte Schmerz und verbesserte die Lebensqualität.
Fragestellung
Wie wirksam ist PEA zur Schmerzlinderung bei verschiedenen Schmerztypen?
Methode
Systematische Suche in PubMed, Embase, Scopus und Cochrane Library; Metaanalyse randomisierter klinischer Studien zu nozizeptivem, neuropathischem und noziplastischem Schmerz.
Ergebnisse
18 Studien mit 1.196 Patient:innen. Schmerzreduktion zugunsten von PEA nach 6 Wochen (SMD –0,9; 95 %-KI –1,60 bis –0,31), 8 Wochen (–0,98; –1,61 bis –0,36) und 24-26 Wochen (–1,16; –2,15 bis –0,17).
Schlussfolgerung der Autor:innen
Die Metaanalyse bestätigte, dass PEA Schmerz wirksam reduziert und die Lebensqualität verbessert, mit signifikanten Vorteilen innerhalb von 4-6 Wochen.
Kernaussagen
- Schmerzreduktion zugunsten von PEA nach 6, 8 und 24-26 Wochen
- Lebensqualität mit schmerzbezogenen Items besser unter PEA
- Wirksam bei nozizeptivem, neuropathischem und noziplastischem Schmerz
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Metaanalyse in der Zeitschrift Nutrition Reviews, online erschienen am 11.01.2025. Verfasst von Isabel Viña und 1 weiteren Autor:innen. Beteiligte Einrichtung: IVBwellness Lab, Valencia, Spain. Hauptthemen laut MEDLINE: Chronic Pain, Ethanolamines, Pain Management, Palmitic Acids. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Context
Chronic pain is a debilitating condition that affects a significant proportion of the population. Palmitoylethanolamide (PEA), a naturally occurring fatty acid amide derived from omega-7 fatty acids, has emerged as a safe and effective alternative for pain management and exerts its effects by interacting with the endocannabinoid system, modulating inflammation, and regulating immune responses.
Objective
A comprehensive meta-analysis was conducted to evaluate the efficacy of PEA in alleviating pain across various pathologies, considering the nociceptive, neuropathic, or nociplastic nature of pain. Data Sources A systematic search was conducted of 4 databases: PubMed, Embase, Scopus, and Cochrane Collaboration Library. Data Extraction Randomized clinical trials were selected for analysis. This meta-analysis included 18 studies involving 1196 patients. Data Analysis Continuous variables were assessed using a standard mean difference (SMD). Heterogeneity was evaluated using the χ2 test and I2 statistics. Pain was significantly reduced in the PEA group at 6 weeks (SMD, –0.9; 95% CI, –1.60 to –0.31), 8 weeks (SMD, –0.98; 95% CI, –1.61 to –0.36), and 24-26 weeks (SMD, –1.16; 95% CI, –2.15 to –0.17). Quality of life, including pain-related items, was significantly higher in the PEA group (SMD, –0.61; 95% CI, –0.93 to –0.30). Significant differences in favor of PEA were observed at 4 (SMD, –0.36; 95% CI, –0.65 to –0.07) and 8 weeks (SMD, –0.66; 95% CI, –1.15 to –0.17). Palmitoylethanolamide was effective for all pain types: nociceptive (SMD, –0.74; 95% CI, –1.42 to –0.06), neuropathic (SMD, –0.97; 95% CI, –1.54 to –0.39), and nociplastic (SMD, –0.59; 95% CI, –1.15 to –0.03).
Conclusions
This meta-analysis confirmed that PEA effectively reduces pain and enhances quality of life, with significant benefits observed within 4-6 weeks of treatment. Palmitoylethanolamide is a promising alternative to chronic opioid analgesics, potentially reducing the risk of opioid abuse and dependency. Systematic Review Registration PROSPERO registration no. CRD42024550546.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IVBwellness Lab, Valencia, Spain.
- Diet, Planetary Health and Performance, Faculty of Health Sciences, Universidad Francisco de Vitoria, Pozuelo, Spain.
ORCID-Profile: Isabel Viña, Miguel López-Moreno
Zitieren
APA
Viña, I., & López-Moreno, M. (2025). Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Nutrition Reviews, 83(7), e1604-e1618. https://doi.org/10.1093/nutrit/nuae203
Vancouver
Viña I, López-Moreno M. Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203
BibTeX
@article{Via2025,
author = {Viña, Isabel and López-Moreno, Miguel},
title = {Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding},
journal = {Nutrition Reviews},
year = {2025},
volume = {83},
number = {7},
pages = {e1604--e1618},
doi = {10.1093/nutrit/nuae203}
}
EUVIMED